Literature DB >> 12065733

Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.

Walter A Volberg1, Bryan J Koci, Weiguo Su, Jing Lin, Jun Zhou.   

Abstract

Several macrolides have been reported to cause QT prolongation and ventricular arrhythmias such as torsades de pointes. To clarify the underlying ionic mechanisms, we examined the effects of six macrolides on the human ether-a-go-go-related gene (HERG)-encoded potassium current stably expressed in human embryonic kidney-293 cells. All six drugs showed a concentration-dependent inhibition of the current with the following IC(50) values: clarithromycin, 32.9 microM; roxithromycin, 36.5 microM; erythromycin, 72.2 microM; josamycin, 102.4 microM; erythromycylamine, 273.9 microM; and oleandomycin, 339.6 microM. A metabolite of erythromycin, des-methyl erythromycin, was also found to inhibit HERG current with an IC(50) of 147.1 microM. These findings imply that the blockade of HERG may be a common feature of macrolides and may contribute to the QT prolongation observed clinically with some of these compounds. Mechanistic studies showed that inhibition of HERG current by clarithromycin did not require activation of the channel and was both voltage- and time-dependent. The blocking time course could be described by a first-order reaction between the drug and the channel. Both binding and unbinding processes appeared to speed up as the membrane was more depolarized, indicating that the drug-channel interaction may be affected by electrostatic responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065733     DOI: 10.1124/jpet.302.1.320

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

Review 1.  Electrical and mechanical stimulation of cardiac cells and tissue constructs.

Authors:  Whitney L Stoppel; David L Kaplan; Lauren D Black
Journal:  Adv Drug Deliv Rev       Date:  2015-07-30       Impact factor: 15.470

2.  QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.

Authors:  Xian Chen; Jessica D Cass; Jenifer A Bradley; Corinn M Dahm; Zhuoqian Sun; Edmund Kadyszewski; Michael J Engwall; Jun Zhou
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

3.  Pentamidine reduces hERG expression to prolong the QT interval.

Authors:  Jason S Cordes; Zhuoqian Sun; David B Lloyd; Jenifer A Bradley; Alan C Opsahl; Mark W Tengowski; Xian Chen; Jun Zhou
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 4.  Short QT syndrome.

Authors:  Ramon Brugada; Kui Hong; Jonathan M Cordeiro; Robert Dumaine
Journal:  CMAJ       Date:  2005-11-22       Impact factor: 8.262

5.  Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Authors:  Yayu Tan; Yadong Chen; Qidong You; Haopeng Sun; Manhua Li
Journal:  J Mol Model       Date:  2011-06-10       Impact factor: 1.810

6.  Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency.

Authors:  Tongtong Yu; Tiesheng Niu
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

7.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

8.  Risk of cardiovascular effects with azithromycin.

Authors:  Ramachandran Kumaresan; Subish Palaian; Santosh Thapa; Pathiyil Ravi Shankar
Journal:  J Clin Diagn Res       Date:  2015-01-01

9.  Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.

Authors:  Franck Potet; Amanda N Lorinc; Sebastien Chaigne; Corey R Hopkins; Raghav Venkataraman; Svetlana Z Stepanovic; L Michelle Lewis; Emily Days; Veniamin Y Sidorov; Darren W Engers; Beiyan Zou; David Afshartous; Alfred L George; Courtney M Campbell; Jeffrey R Balser; Min Li; Franz J Baudenbacher; Craig W Lindsley; C David Weaver; Sabina Kupershmidt
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

Review 10.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.